Keurig Dr Pepper Inc.

▲ Bull Case

• ◆Dr Pepper is the highest-quality single-trademark moat in US beverages outside of Coke itself. The brand has taken US CSD share at 50–100bps annually for the past 5+ years (now #2 trademark by volume), driven by unique flavor differentiation and Gen-Z acceptance. As the category de-weights sugary drinks (GLP-1 tailwind for zero-sugar SKUs), Dr Pepper's flavor portfolio is positioned to capture share from vanilla colas. The Refreshment Beverages Co. spin-co will trade at an 18–20x EBITDA premium to peers, justified by durable 4–5% organic growth + 30% cash margins.
• ◆JDE Peet's synergies are achievable and material to deal thesis. GHOST's integration (Jan 2025) delivered 6.2pp of volume contribution in 2025 vs. modeled 4–5pp, validating KDP's ability to scale acquired brands through its DSD network. JDE has $200–400M of identified cost-synergy targets (G&A consolidation, procurement scale, manufacturing footprint optimization). De-leveraging from 4.5x to <3.5x requires $300M+ of net synergies and modest organic growth (3–4%); both are embedded in management guidance and achievable within KDP's execution track record.
• ◆Split-company structure unlocks long-term value by eliminating sector-multiple drag and enabling focused capital allocation. Global Coffee (JDE) trades at 11–13x EBITDA on mature low-single-digit volume growth; Refreshment Beverages trades at 16–20x on strong growth + moat. Today, the blended 14–15x multiple penalizes both. Separate listing creates proper capital markets perception, separate dividend policies (RBC high-yield, coffee focused on deleveraging), and focused M&A strategies.

▼ Bear Case

• ◆JDE Peet's acquisition is strategically scattershot and operationally distracting. KDP went into the deal already managing a complex three-segment portfolio plus a full-blown GHOST integration. Adding a global, 150-country coffee business with different supply chains, regulatory environments, and embedded cost structures (JDE Peet's runs 22% EBITDA margin vs. KDP 28%) creates a multi-year distraction. First real test is Q3 2026; if synergy traction is <50% of plan, bear case probability rises sharply.
• ◆GLP-1 drug adoption is a structural headwind to sugary-beverage volumes that consensus under-weights. ~10% of US adults now use semaglutide-class weight-loss drugs; studies show 33% of heavy soda drinkers quit entirely and 24% of daily coffee drinkers reduce consumption. This is a persistent 50–150bps demand headwind on legacy CSDs + coffee volumes that forces mix-shift and/or pricing to compensate. Energy/zero-sugar can offset some volume loss, but the math is unfavorable: zero-sugar has lower margins and energy is a competitive battleground.
• ◆Convertible preferred dilution is under-discussed and creates per-share EPS drag through 2030. KDP issued $4.5B of convertible preferred (Apollo/KKR) at expected 7–9% coupon with conversion likely ~30% above deal close price (~$32–33/share). At conversion in 2028–2030, true diluted share count rises by ~140–180M shares (~10–12% dilution), pushing diluted EPS ~7–9% lower than reported. This overhang makes the 24-month bull case weaker than consensus price targets imply.

“Consensus leans constructive but cautious (10 Buy / 7 Hold / 0 Sell; mean 12-month PT ~$35.47 ~21% upside), embedding ~30% probability of the full bull case. Canonical disagreement boils down to three sub-debates: (1) JDE Integration — Value Creation or Distraction? Bulls argue $200–400M cost synergies are achievable given overlapping G&A + procurement; Bears counter that KDP lacks track record in emerging-market coffee operations and integration is 2x the complexity of prior deals. (2) Split Antitrust Clearance — Probability & Timeline? Bulls expect FTC approval 2027–2028 unlocking 15–25% value; Bears worry about forced divestitures and delayed timeline. (3) Dr Pepper Share Gains — Durable or Cyclical? Bulls argue the 80+ year trademark, unique flavor profile, and Gen-Z acceptance support sustained 50–100bps annual share gains; Bears contend gains are cyclical and long-term normalization is likely.”

• ◆Q3 2026 earnings (early October 2026): First full quarter of post-JDE consolidation. Beat = +5–7% stock re-rating; miss >10% = –12–15%. This is the credibility reset event.
• ◆2027 Guidance + Synergy Update (Jan–Feb 2027): Management will quantify $300M+ annualized synergy pipeline with phasing. Confirmation of 2027–2028 FCF deleveraging trajectory will support stock = +3–5%. Any downgrade = –8–10%.
• ◆FTC Antitrust Approval of Split (likely 2H 2027, earliest 2027-Q3): Approval signals value unlocking is on track; could catalyze +8–12% re-rating as market reprices sum-of-parts. Delay or conditional approval (forced divestitures) = –10–15%.

• ◆JDE synergy shortfall >30% (Operational, Very High severity, 25% probability): Diversified synergy sources (G&A, procurement, mfg footprint) provide some recovery optionality, but miss >30% breaks deal ROI.
• ◆GLP-1 structural volume headwind faster than modeled (Secular, High severity, 40% probability): 50–150bps annual demand drag on legacy CSDs + coffee; zero-sugar mix shift and energy growth can only partially offset.
• ◆Split antitrust blocked or heavily conditioned (Regulatory, High severity, 20% probability): Forced asset sales or extended delay would eliminate split optionality; worst case = 2+ year delay, not outright block.
• ◆Leverage stalls >4.2x through 2027 (Financial, High severity, 30% probability): Forces dividend guidance concern or asset sale; refinancing risk if rates spike and spreads widen >100bps.
• ◆Interest-rate spike + refinancing pressure (Macro/Rates, Medium severity, 25% probability): $9B of new term debt issued at 2026 rates; 100bps rise = ~$90M annual interest cost increase, compressing FCF for deleveraging.